Michael Pfleiderer

607 total citations
28 papers, 429 citations indexed

About

Michael Pfleiderer is a scholar working on Infectious Diseases, Epidemiology and Genetics. According to data from OpenAlex, Michael Pfleiderer has authored 28 papers receiving a total of 429 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Infectious Diseases, 10 papers in Epidemiology and 8 papers in Genetics. Recurrent topics in Michael Pfleiderer's work include SARS-CoV-2 and COVID-19 Research (9 papers), Virus-based gene therapy research (8 papers) and Influenza Virus Research Studies (6 papers). Michael Pfleiderer is often cited by papers focused on SARS-CoV-2 and COVID-19 Research (9 papers), Virus-based gene therapy research (8 papers) and Influenza Virus Research Studies (6 papers). Michael Pfleiderer collaborates with scholars based in Germany, Austria and Slovakia. Michael Pfleiderer's co-authors include Stuart G. Siddell, E. G. Routledge, Falko G. Falkner, Friedrich Dorner, Roland H. Stauber, Michael A. Skinner, Christian K. Schneider, Ted A. Torrey, Egbert Flory and Nobutaka Hirokawa and has published in prestigious journals such as Nucleic Acids Research, Nature Biotechnology and Journal of Virology.

In The Last Decade

Michael Pfleiderer

28 papers receiving 414 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Michael Pfleiderer Germany 14 172 138 110 89 86 28 429
Devra Huey United States 12 319 1.9× 215 1.6× 110 1.0× 88 1.0× 57 0.7× 18 583
Lucas J. Adams United States 12 410 2.4× 127 0.9× 68 0.6× 86 1.0× 50 0.6× 22 552
Scott Coley United States 7 158 0.9× 98 0.7× 66 0.6× 111 1.2× 22 0.3× 9 379
Takehiro Ura Japan 8 278 1.6× 85 0.6× 37 0.3× 159 1.8× 99 1.2× 8 496
Jan Kövamees Sweden 14 88 0.5× 481 3.5× 83 0.8× 60 0.7× 163 1.9× 25 528
Atsushi Sugiura Japan 14 251 1.5× 699 5.1× 107 1.0× 81 0.9× 154 1.8× 32 881
Brenda Larkin United States 8 262 1.5× 199 1.4× 57 0.5× 162 1.8× 53 0.6× 9 521
Kim E. Schmidt Germany 5 417 2.4× 96 0.7× 86 0.8× 287 3.2× 58 0.7× 6 678
Kersi Katrak United Kingdom 9 177 1.0× 116 0.8× 51 0.5× 102 1.1× 60 0.7× 10 458
Santiago Dueñas‐Carrera Cuba 17 105 0.6× 380 2.8× 58 0.5× 164 1.8× 31 0.4× 46 655

Countries citing papers authored by Michael Pfleiderer

Since Specialization
Citations

This map shows the geographic impact of Michael Pfleiderer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Pfleiderer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Pfleiderer more than expected).

Fields of papers citing papers by Michael Pfleiderer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Pfleiderer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Pfleiderer. The network helps show where Michael Pfleiderer may publish in the future.

Co-authorship network of co-authors of Michael Pfleiderer

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Pfleiderer. A scholar is included among the top collaborators of Michael Pfleiderer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Pfleiderer. Michael Pfleiderer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kretzschmar, Evelyne, Heide Muckenfuß, & Michael Pfleiderer. (2018). Official batch control of influenza vaccines: Is it still useful?. Vaccine. 36(17). 2364–2370. 1 indexed citations
2.
3.
Pfleiderer, Michael, et al.. (2016). New bone post-processing tools in forensic imaging: a multi-reader feasibility study to evaluate detection time and diagnostic accuracy in rib fracture assessment. International Journal of Legal Medicine. 131(2). 489–496. 18 indexed citations
4.
Lambach, Philipp, Alba Álvarez, Siddhivinayak Hirve, et al.. (2015). Considerations of strategies to provide influenza vaccine year round. Vaccine. 33(47). 6493–6498. 32 indexed citations
5.
Pfleiderer, Michael & Ole Wichmann. (2015). Von der Zulassung von Impfstoffen zur Empfehlung durch die Ständige Impfkommission in Deutschland. Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz. 58(3). 263–273. 3 indexed citations
6.
Pfleiderer, Michael, Jean‐Hugues Trouvin, Daniel Brasseur, et al.. (2014). Summary of knowledge gaps related to quality and efficacy of current influenza vaccines. Vaccine. 32(35). 4586–4591. 10 indexed citations
7.
Li, Xuguang, Carolyn A. Wilson, Robert Ball, et al.. (2013). A global regulatory science agenda for vaccines. Vaccine. 31. B163–B175. 30 indexed citations
8.
9.
Pfleiderer, Michael. (2011). Grippe‐Impfstoffe. Herstellung, Zulassung und Weiterentwicklung. Pharmazie in unserer Zeit. 40(2). 126–134. 1 indexed citations
10.
Pfleiderer, Michael, et al.. (2010). First-in-human clinical trials with vaccines—what regulators want. Nature Biotechnology. 28(9). 910–916. 21 indexed citations
11.
Pfleiderer, Michael. (2010). Pandemische Influenzaimpfstoffe. Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz. 53(12). 1242–1249. 3 indexed citations
12.
13.
Pfleiderer, Michael, et al.. (2008). Vaccination Safety Update. Deutsches Ärzteblatt international. 105(34-35). 590–5. 4 indexed citations
14.
Pfleiderer, Michael, Johannes Löwer, & Reinhard Kurth. (2001). Cold-attenuated live influenza vaccines, a risk-benefit assessment. Vaccine. 20(5-6). 886–894. 13 indexed citations
15.
Himmelspach, Michèle, Michael Pfleiderer, Bernhard Fischer, et al.. (2000). Recombinant Human Factor X. Thrombosis Research. 97(2). 51–67. 17 indexed citations
16.
Pfleiderer, Michael, Falko G. Falkner, & Friedrich Dorner. (1996). Deletion of the myristylation signal allows high-level production of the hepatitis B virus large surface glycoprotein preS1 with vaccinia virus recombinants. Gene. 176(1-2). 131–137. 2 indexed citations
17.
Pfleiderer, Michael, Falko G. Falkner, & Friedrich Dorner. (1995). Requirements for Optimal Expression of Secreted and Nonsecreted Recombinant Proteins in Vaccinia Virus Systems. Protein Expression and Purification. 6(5). 559–569. 11 indexed citations
18.
Flory, Egbert, et al.. (1993). Induction of protective immunity against coronavirus‐induced encephalomyelitis: Evidence for an important role of CD8+ T cells in vivo. European Journal of Immunology. 23(8). 1757–1761. 20 indexed citations
19.
Pfleiderer, Michael, E. G. Routledge, & Stuart G. Siddell. (1990). Functional Analysis of the Coronavirus MHV-JHM Surface Glycoproteins in Vaccinia Virus Recombinants. Advances in experimental medicine and biology. 276. 21–31. 10 indexed citations
20.
Pfleiderer, Michael, Michael A. Skinner, & Stuart G. Siddell. (1986). Coronavirus MHV-JHM: nucleotide sequence of the mRNA that encodes the membrane protein. Nucleic Acids Research. 14(15). 6338–6338. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Devra Huey Breakdown of academic impact, for papers by Lucas J. Adams Breakdown of academic impact, for papers by Scott Coley Breakdown of academic impact, for papers by Takehiro Ura Breakdown of academic impact, for papers by Jan Kövamees Breakdown of academic impact, for papers by Atsushi Sugiura Breakdown of academic impact, for papers by Brenda Larkin Breakdown of academic impact, for papers by Kim E. Schmidt Breakdown of academic impact, for papers by Kersi Katrak Breakdown of academic impact, for papers by Santiago Dueñas‐Carrera
Rankless by CCL
2026